Methylphenidate Stada

Methylphenidate hydrochloride, the active ingredient in Methylphenidate Stada, is a central nervous system stimulant presented as an oral dosage form for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults. GNH USA supplies Methylphenidate Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Stada is a central nervous system stimulant used in specific neurobehavioral disorders. - Attention deficit hyperactivity disorder (ADHD): improves focus, reduces hyperactivity and impulsivity, supporting academic and occupational performance. - Narcolepsy: lessens excessive daytime sleepiness and reduces the frequency of cataplexy episodes, helping maintain wakefulness.

Methylphenidate Stada may cause a range of adverse reactions.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced desire for food, potentially leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis or severe agitation: hallucinations, delusional thinking. - Priapism: prolonged, painful erection. - Seizures: convulsive episodes, especially in predisposed individuals.

Before prescribing Methylphenidate Stada, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate blood pressure and heart rate, especially in patients with pre‑existing heart disease. - Psychiatric history: monitor for emergence of psychotic symptoms or mood disturbances. - Growth monitoring: track height and weight in pediatric patients due to appetite suppression. - Substance misuse risk: assess for history of drug abuse, as the drug has potential for dependence. - Drug‑specific contraindications: avoid use in patients with known hypersensitivity to methylphenidate. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Methylphenidate Stada can interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Sympathomimetic agents (e.g., ephedrine): may cause severe cardiovascular stimulation. - Tricyclic antidepressants: increased risk of arrhythmias and hypertension.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels. - Antihypertensive drugs: potential reduction in blood‑pressure‑lowering effect. - Antacids: may alter absorption rate. - Alcohol: can enhance central nervous system side effects.